Publicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (47)

2024

  1. Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis

    Kidney International, Vol. 105, Núm. 1, pp. 177-188

  2. Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis

    Nephrology Dialysis Transplantation, Vol. 39, Núm. 2, pp. 328-340

2023

  1. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876

  2. Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

    Kidney360, Vol. 4, Núm. 5, pp. 659-672

  3. Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis

    Nefrologia, Vol. 43, Núm. 1, pp. 6-47

2022

  1. Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression

    Journal of the American Society of Nephrology : JASN, Vol. 33, Núm. 2, pp. 291-303

  2. Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy

    Clinical Kidney Journal, Vol. 15, Núm. 9, pp. 1737-1746

  3. Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, Núm. 7, pp. 1270-1280

2021

  1. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

    Kidney International, Vol. 99, Núm. 4, pp. 986-998

  2. Validation of a Histologic Scoring Index for C3 Glomerulopathy

    American Journal of Kidney Diseases, Vol. 77, Núm. 5, pp. 684-695.e1

2020

  1. Mycophenolate mofetil in c3 glomerulopathy and pathogenic drivers of the disease

    Clinical Journal of the American Society of Nephrology, Vol. 15, Núm. 9, pp. 1287-1298

  2. Risk factors for non-diabetic renal disease in diabetic patients

    Clinical Kidney Journal, Vol. 13, Núm. 3, pp. 380-388

2019

  1. IgA nephropathy in elderly patients

    Clinical Journal of the American Society of Nephrology, Vol. 14, Núm. 8, pp. 1183-1192

  2. Returning to haemodialysis after kidney allograft failure: A survival study with propensity score matching

    Nephrology Dialysis Transplantation, Vol. 34, Núm. 4, pp. 667-672

  3. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome

    Kidney International, Vol. 96, Núm. 4, pp. 995-1004

2018

  1. Changes in the clinical presentation of immunoglobulin A nephropathy: Data from the Spanish Registry of Glomerulonephritis

    Nephrology Dialysis Transplantation, Vol. 33, Núm. 3, pp. 472-477

2017

  1. Monoclonal gammopathies of renal significance

    Nefrologia

  2. The Combination of Beta Blockers and Renin-Angiotensin System Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study

    Journal of Computational Design and Engineering, Vol. 4, Núm. 3, pp. 665-675

  3. The Fatty Kidney: Obesity and Renal Disease

    Nephron, Vol. 136, Núm. 4, pp. 273-276

2016

  1. CD163-macrophages are involved in rhabdomyolysis-induced kidney injury and may be detected by MRI with targeted gold-coated iron oxide nanoparticles

    Theranostics, Vol. 6, Núm. 6, pp. 896-914